Advanced Non-animal Models in Biomedical Research

Breast Cancer

Executive Summary
This Executive Summary describes a study conducted by the JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) to identify current and emerging non-animal models and methods being used for biomedical research related to breast cancer.


Contact information
European Commission, Joint Research Centre (JRC), Chemical Safety and Alternative Methods Unit (F3)
Via E. Fermi 2749, I-21027 Ispra (VA), Italy
JRC-F3-ENQUIRIES@ec.europa.eu

EU Science Hub
https://ec.europa.eu/jrc

JRC122309

EUR 30334/1 EN


© European Union, 2020

The reuse policy of the European Commission is implemented by the Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Except as otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (https://creativecommons.org/licenses/by/4.0/). This means that reuse is allowed provided appropriate credit is given and any changes are indicated. For any use or reproduction of photos or other material that is not owned by the EU, permission must be sought directly from the copyright holders.

Design and layout: Debora Valsesia and Adelaide Dura.

Advanced Non-animal Models in Biomedical Research

Breast Cancer

Executive Summary
Executive Summary

Breast cancer is the most common cancer among women in the European Union and worldwide. The European Cancer Information System (ECIS) indicates that in the EU over 355,000 women were diagnosed with breast cancer in 2020 (13.3% of all cancer diagnoses).

Human-based models can better address heterogeneity of human breast cancer

Preclinical breast cancer research currently relies heavily on animal models, mostly rodents. However, animal models only capture limited aspects of human breast cancer disease.

For this reason, research is gradually moving towards the development of advanced non-animal systems that can recreate the heterogeneous environment peculiar to human breast cancer.

In this context, the JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) carried out a study to survey and characterise the state-of-the-art of non-animal models being used in biomedical research.

The review identified promising non-animal approaches being used for breast cancer. These are based mainly on techniques that use cells and tissues cultured in the laboratory.

Despite advances in early detection and understanding of the molecular basis of breast cancer biology, approximately 30% of patients with early-stage breast cancer have recurrent disease, which is metastatic in most cases. To offer more effective treatments with fewer and less severe side effects, selecting therapies best suited to the individual patient and the clinical and molecular characteristics of the tumour is a necessity.

(in vitro methods), computer modelling and simulation (in silico methods) or cells and tissues explanted from a patient (ex vivo methods).

**Categories of advanced models and their applications**

The EURL ECVAM study involved an extensive review of scientific literature published from January 2014 to March 2019 that identified 935 papers describing relevant non-animal models for breast cancer.

*In vitro* models based on a variety of immortalised cell lines were the most popular approach used for breast cancer research (see Box 2). These cell lines are mostly commercially available and already qualified.

While 2D cell lines are convenient research models to study breast cancer, they are relatively simplistic. Thus the use of 3D culture conditions has increased over time reaching in 2018 the publication level of 2D models. 3D models can better mimic the complexity and heterogeneity that characterise human breast tumours.

The use of a scaffolding system emerged as the main technique employed to generate 3D models, followed by organoids and spheroids, known as mammospheres. Different culture conditions were also observed in combination with microfluidic systems.

It was found that *in silico* methods are sometimes used in combination with *in vitro* models. This still represents a minor niche, but it is worth highlighting their applications.
Executive Summary

The use of machine learning in predictive modelling is a very interesting approach, especially in drug development and for testing new therapeutic strategies.

Although 5% to 10% of breast cancer can be hereditary, the high incidence of the disease highlights the lack of knowledge about the events triggering breast cancer initiation and whether it skips immunological recognition. This review found that non-animal models are employed mainly to study cancer initiation and development in order to fill this knowledge gap and discover the molecular basis of the driving events.

Box 1. What is tumour heterogeneity?

Heterogeneity is a word of Greek origin meaning “different kinds” and indicates a composition of different constituents rather than a uniform mass.

Tumours develop as a clonal process beginning with a single transformed cell. Therefore, heterogeneity in tumours is observed between different patients. Not all malignant cells within a tumour are the same and heterogeneity occurs also within a single patient.

Some tumours such as breast cancer are characterised by a high degree of heterogeneity. These variations have serious implications for patients ranging from the initial diagnosis to the treatment of metastatic disease.

Diagnosis often relies on needle biopsy, a procedure in which small samples of cells are extracted from a tumour and analysed. This method of sampling may not be representative of the entire tumour mass, leading leading for example to uncertainty in selecting the right therapy.

With metastatic progression, heterogeneity can be even more pronounced, raising the question of which lesion to sample in order to identify the most useful treatment targets.

Box 2. Immortalised cell lines

Immortalised cell lines have been the workhorse in biomedical research labs for decades. They are cells capable of renewing themselves indefinitely in artificial environments due to mutations, such as those found in tumours, or introduced through genetic manipulation.

In breast cancer studies the most commonly used cell line is MCF-7, which was established in 1973 at the Michigan Cancer Foundation. It was isolated from an invasive ductal breast cancer which developed in a Caucasian nun, Frances Mallon. Since then, a number of different breast cancer cell lines have been developed and used for in vitro cell culture or in animal experiments using xenografts.

Immortalised cell lines can be grown in 3D structures to better simulate the tumour microenvironment that it is well known to play an active role in tumour growth and progression. 3D systems, which can also be derived from tumour biopsies, stem cells or primary cell cultures, are developed through a wide range of technologies, such as scaffolds, spheroids – also called mammospheres – and organoids.

Structure of a spheroid derived from human breast cancer stem cells. ©Trinh, N., Dang, N., Tran, D., and Pham, P. (2016), Taraxacum officinale dandelion extract efficiently inhibited the breast cancer stem cell proliferation. Biomedical Research and Therapy, 3(07), 735-741 under CC BY 4.0.
The knowledge base

This study has produced a unique and highly curated knowledge base that contains detailed descriptions of 935 non-animal models being used for breast cancer research. It is freely available to download from the EURL ECVAM Collection in the JRC Data Catalogue, together with a JRC Technical report that describes the review methodology and presents the main findings (see Box 3).

This unique knowledge base can serve the needs of multiple stakeholders:

- researchers can identify models and methods that can be adapted and applied to tackle their own research questions;
- educators can provide the latest information on the state-of-the-art to their students;
- funding bodies can consider trends, identify impactful research avenues and target promising areas for investment;
- project evaluation committees can ensure that project proposers have properly considered the use of non-animal models and methods in their research proposals;
- National Contact Points and National Committees can ensure proper knowledge sharing on non-animal methods within Member State networks and organisations involved in biomedical research using animals.

Box 3. Knowledge base of advanced non-animal models

This study is a part of a series that EURL ECVAM is carrying out to review available and emerging non-animal models being used for research in seven disease areas. Details on the published studies are available on the EURL ECVAM website.

In this study around 120,000 peer-reviewed publications on breast cancer were initially retrieved and screened for representative papers describing innovative and promising advanced non-animal models.

An important outcome of this study is a highly curated knowledge base containing detailed descriptions of 935 non-animal models being used for breast cancer. It is easily downloadable as a spreadsheet file from the EURL ECVAM collection in the JRC Data Catalogue.

This knowledge base is complemented with a Technical Report that provides an in-depth analysis of the models identified and of the review methodology used.
Findings of this study can also inform aspects of policy making regarding the protection of animals used for scientific purposes, setting of research priorities to progress the development and uptake of non-animal methods, and the promotion of modern human-relevant scientific approaches to combat diseases such as cancer.

Finally, this knowledge base can serve as a means to explore the strengths and limitations of both animal and non-animal models used in biomedical research, to stimulate healthy scientific debate, to challenge mind-sets, and to pave the way for doing better and more predictive science. Thus the knowledge base can act as a bridge across methods and disciplines in the biosciences to improve biomedical research for the ultimate benefit of patients and society.

GETTING IN TOUCH WITH THE EU

IN PERSON
All over the European Union there are hundreds of Europe Direct information centres. You can find
the address of the centre nearest you at: https://europa.eu/european-union/contact_en

ON THE PHONE OR BY EMAIL
Europe Direct is a service that answers your questions about the European Union. You can contact
this service:
- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696, or
- by electronic mail via: https://europa.eu/european-union/contact_en.

FINDING INFORMATION ABOUT THE EU

ONLINE
Information about the European Union in all the official languages of the EU is available

EU PUBLICATIONS
You can download or order free and priced EU publications from EU Bookshop at: https://publications.europa.eu/en/publications. Multiple copies of free publications may be obtained by contacting Europe Direct or your local information centre (see https://europa.eu/european-union/contact_en).

EU LAW AND RELATED DOCUMENTS
For access to legal information from the EU, including all EU law since 1952
in all the official language versions, go to EUR-Lex at: http://eur-lex.europa.eu.

OPEN DATA FROM THE EU
The EU Open Data Portal (http://data.europa.eu/euodp/en) provides access to datasets from the EU.
Data can be downloaded and reused for free, for both commercial and non-commercial purposes.
JRC Mission
As the science and knowledge service of the European Commission, the Joint Research Centre’s mission is to support EU policies with independent evidence throughout the whole policy cycle.